deltatrials
Completed PHASE2 NCT00139750

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking

Sponsor: Pfizer

Conditions Smoking Cessation
Interventions CP-526,555 (varenicline)
Updated 5 times since 2017 Last updated: Jun 1, 2007 Started: Dec 31, 2004 Completion: Feb 28, 2006

A PHASE2 clinical study on Smoking Cessation, this trial is completed. The trial is conducted by Pfizer and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beppu-shi, Japan, Edogawa-ku, Japan, Fukuoka, Japan, Hamamatsu, Japan, Minato-ku, Japan, Musashino, Japan, Noda, Japan, Ohita, Japan, Sapporo, Japan, Setagaya-ku, Japan and 5 more location s